T. Geiser (Bern, Switzerland), D. Stolz (Basel, Switzerland)
Late Breaking Abstract - Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children: a randomized controlled trial
T. Ruffles (Brighton, United Kingdom), V. Goyal (Brisbane, Australia), J. Marchant (Brisbane, Australia), B. Masters (Brisbane, Australia), S. Yerkovich (Brisbane, Australia), H. Buntain (Brisbane, Australia), A. Cook (Brisbane, Australia), A. Schultz (Perth, Australia), L. Versteegh (Darwin, Australia), A. Chang (Brisbane, Australia)
|     |
Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial
E. Wittermans (Nieuwegein, Netherlands), S. Vestjens (Nieuwegein, Netherlands), S. Spoorenberg (Nieuwegein, Netherlands), W. Blok (Amsterdam, Netherlands), J. Grutters (Nieuwegein, Netherlands), R. Janssen (Nijmegen, Netherlands), G. Rijkers (Middelburg, Netherlands), F. Smeenk (Eindhoven, Netherlands), P. Voorn (Nieuwegein, Netherlands), E. Van De Garde (Nieuwegein, Netherlands), W. Bos (Nieuwegein, Netherlands)
| |
Wrap-up by discussant and discussion
S. Aliberti (Milano (MI), Italy)
| |
Late Breaking Abstract - Effects of long-term Tobramycin Inhalation Solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. The BATTLE Randomized Controlled Trial
L. Terpstra (Alkmaar (NH), Netherlands), I. Bronsveld (Utrecht, Netherlands), J. Doodeman (Alkmaar (NH), Netherlands), W. Rozenmeijer (Alkmaar (NH), Netherlands), H. Heijerman (Utrecht, Netherlands), W. Boersma (Alkmaar (NH), Netherlands)
| |
Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study
J. Chalmers (Dundee, United Kingdom), C. Haworth (Cambridge, United Kingdom), M. Metersky (Farmington, United States of America), M. Loebinger (London, United Kingdom), F. Blasi (Milan, Italy), O. Sibila (Barcelona, Spain), A. O'Donnell (Washington DC, United States of America), E. Sullivan (Bridgewater, NJ, United States of America), K. Mange (Bridgewater, NJ, United States of America), C. Fernandez (Bridgewater, NJ, United States of America), J. Zou (Bridgewater, NJ, United States of America), C. Daley (Dundee (Angus), United States of America)
| |
Late Breaking Abstract - Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
J. Chalmers (Dundee (Angus), United Kingdom), D. Cipolla (Hayword, United States of America), B. Thompson (Owings Mills, United States of America), A. Davis (Clayton, United States of America), A. O'Donnell (Washington, United States of America), G. Tino (Philadelphia, United States of America), I. Gonda (Hayward, United States of America), C. Haworth (Cambridge, United Kingdom), J. Froehlich (Hayward, United States of America)
| |
Wrap-up by discussant and discussion
G. Rohde (Frankfurt am Main, Germany)
| |